Harmony Biosciences (HRMY) Set to Announce Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is set to post its quarterly earnings results before the market opens on Tuesday, April 30th. Analysts expect Harmony Biosciences to post earnings of $0.64 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Thursday, February 22nd. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.29). The firm had revenue of $168.40 million for the quarter, compared to analysts’ expectations of $168.90 million. Harmony Biosciences had a net margin of 22.16% and a return on equity of 27.49%. The firm’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.01 EPS. On average, analysts expect Harmony Biosciences to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Harmony Biosciences Stock Up 1.3 %

HRMY stock opened at $29.32 on Friday. The firm has a market cap of $1.67 billion, a PE ratio of 13.83, a PEG ratio of 0.40 and a beta of 0.73. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.72 and a current ratio of 2.75. The firm’s 50 day moving average price is $31.37 and its 200-day moving average price is $29.96. Harmony Biosciences has a one year low of $18.61 and a one year high of $39.26.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 11,979 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $32.00, for a total transaction of $383,328.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 30.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Friday, April 12th. Bank of America reaffirmed an “underperform” rating and set a $30.00 price target on shares of Harmony Biosciences in a research report on Tuesday, January 2nd. Mizuho cut their target price on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 9th. Finally, The Goldman Sachs Group boosted their target price on Harmony Biosciences from $25.00 to $28.00 and gave the company a “sell” rating in a research report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.63.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.